LSL Pharma Group Inc. (LSL.V)
| Previous close | 0.4500 |
| Open | 0.4200 |
| Bid | 0.4300 x N/A |
| Ask | 0.4500 x N/A |
| Day's range | 0.4200 - 0.4500 |
| 52-week range | 0.3500 - 0.5700 |
| Volume | |
| Avg. volume | 39,975 |
| Market cap | 48.602M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
LSL Pharma Group Enters Into Binding Agreement to Acquire Quebec Competitor
Transaction expected to increase annual revenues by 15-20%Acquisition to boost overall profitabilityTransaction expected to close by end of Q2-24 BOUCHERVILLE, Québec, May 06, 2024 (GLOBE NEWSWIRE) -- LSL PHARMA GROUP INC. (TSXV: LSL) ("the Company" or "LSL Pharma"), a Canadian integrated pharmaceutical company, is pleased to announce that it has entered into a binding Letter of Intent ("LOI") to acquire profitable privately held, Quebec-based competing contract drug manufacturer ("CDMO") specia
- GlobeNewswire
LSL Pharma Group Reports Its Fourth Quarter and Year-End 2023 Results and Highlights
FY-2023 Revenues increased by 22% at $10.0 million compared to $8.2 million for FY-2022, a $1.8 million increase.Gross margins for FY-2023 up $3.8 million compared to FY-2022Net loss for FY-2023 of $8.5 million compared to $8.1 million for FY-2022Q4-2023 Revenues of $3.5 million, up 51% over Q4-2022 revenues of $2.3 millionQ4-2023 EBITDA profit of $0.3 million compared to an EBITDA loss of $2.2 million for Q4-2022Q4-2023 Net loss of $0.5 million compared to a net loss of $3 million for Q4-2022In
- GlobeNewswire
LSL Pharma Group Secures $3.8 Million as the Second and Final Tranche of Its Private Placement of Units
BOUCHERVILLE, Quebec, April 24, 2024 (GLOBE NEWSWIRE) -- LSL PHARMA GROUP INC. (TSXV: LSL) (the "Corporation" or "LSL Pharma"), a Canadian integrated pharmaceutical company, today announced the second and final tranche of its private placement financing of Units (as defined hereafter) for $3.8 million representing the second closing of the upsized $7.5 million non-brokered private placement announced on April 11, 2024 (the “Financing”). The second tranche follows an initial first closing of $2.7
